| Program Faculty ................................................................. | i |
| Sponsorship and CME Credit .................................................. | ii |
| CME Activity Assessment and Evaluation .................................. | iv |

**Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents**

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Tim G. Eisen, Jeffrey Engelman, Glenwood D. Goss, Daniel A. Haber, John V. Heymach, Pasi A. Jänne, Bruce E. Johnson, David H. Johnson, Rogerio C. Lilenbaum, Matthew Meyerson, Alan B. Sandler, Lecia V. Sequist, Jeffrey Settleman, Kwok-Kin Wong, and Carol S. Hart .............................................. 4365s

**The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors**

Jeffrey A. Engelman and Lewis C. Cantley ........................................... 4372s

**Her2-Targeted Therapies in Non–Small Cell Lung Cancer**

Charles Swanton, Andy Futreal, and Tim Eisen ....................................... 4377s

**Genomic Approaches to Lung Cancer**

Roman K. Thomas, Barbara Weir, and Matthew Meyerson ......................... 4384s

**“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation**

Sreenath V. Sharma, Michael A. Fischbach, Daniel A. Haber, and Jeffrey Settleman ............................................. 4392s

**Mouse Models of Lung Cancer**

Amit Dutt and Kwok-Kin Wong .................................................................. 4396s

**Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients**

Lecia V. Sequist, Victoria A. Joshi, Pasi A. Jänne, Daphne W. Bell, Panos Fidias, Neal I. Lindeman, David N. Louis, Jeffrey C. Lee, Eugene J. Mark, Janina Longtime, Peter Verlander, Raju Kucherlapati, Matthew Meyerson, Daniel A. Haber, Bruce E. Johnson, and Thomas J. Lynch ............................................. 4403s

**Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?**

Rafal Dziadziuszko, Fred R. Hirsch, Marileila Varella-Garcia, and Paul A. Bunn, Jr. ........................................... 4409s

**Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors**

Pasi A. Jänne and Bruce E. Johnson ............................................. 4416s

**Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways**

Alan Sandler and Roy Herbst ............................................. 4421s

**Strategies to Enhance Epidermal Growth Factor Inhibition: Targeting the Mevalonate Pathway**

Jim Dimitroulakos, Ian A. Lorimer, and Glenwood Goss ................................. 4426s

**The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer**

Rogerio C. Lilenbaum ........................................................................ 4432s

**Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer**

Bruce E. Johnson and Pasi A. Jänne ............................................. 4436s

**Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer**

John V. Heymach, Monique Nilsson, George Blumenschein, Vassiliki Papadimitrakopoulou, and Roy Herbst ............................................. 4441s

**Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition**

Alex A. Adjei ........................................................................ 4446s

**Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer**

David H. Johnson ........................................................................ 4451s